Wall Street's muted response after HHS released the long await list of ten Part D drugs slated for price negotiation under the Inflation Reduction Act. While there were some surprises (e.g., Farxiga, Stelara, and Entresto), analysts clearly believe the news will NOT have that much financial impact on drugmakers. (Leerink called the announcement “immaterial” in a note to investors.)
read full article ›Our co-founder and chairman has some thoughts on recent moves by CVS Health.
read full article ›One week after Blue Shield of CA's announced it was dropping CVS CareMark as its overall PBM and contracting with new vendors such as Amazon and Mark Cuban Cost Plus Drug Company, PBC, comes this: CVS Health is forming a new subsidiary Cordavis to work with drugmakers to produce and commercialize biosimilars. The first partnership on the docket: a tie-up with Sandoz for its Humira #biosimilar #Hyrimoz
read full article ›For many #lifesciences companies, employers are a black box. These survey findings from Business Group on Health help elucidate some of the top priorities of a key #stakeholder in the healthcare #ecosystem.
read full article ›Just when you thought it was a time for a summer news slowdown, Blue Shield CA lays down the gauntlet. Aiming to reimagine pharmacy services, the payer is completely rethinking its drug supply chain - and the vendors who provide the services moving from the integrated model to a something more decentralized where Blue Shield retains control.
read full article ›Peter Neumann and the team at Tufts analyze IRA's impact on the development of drugs for rare diseases and what's now known as the "single orphan conundrum." Their take: "Our analysis suggests that the potential foregone follow-on indication approvals for serious illness and unmet needs could be nontrivial."
read full article ›Important read from Matthew Herper at STAT that reminds readers of the shortcomings of our drug pricing system (and an amazing zen koan analogy). As our CEO Jeff Berkowitz likes to say, so many of us who work in market access "have been scarred by the disconnects in the US healthcare system."
read full article ›Are you curious about new solutions that empower Medicare patients to better afford their meds? Did you miss our July 19 webinar on RE Assist, an AI-based platform that helps solve the Medicare copay problem?
read full article ›With the advent of decentralized manufacturing and other tools to lower the cost of goods, new business models that empower centers of excellence to become manufacturers will emerge. The broader business question is which indications are best suited for not-for-profit institutions and which are best suited for biotech and pharma. And right now that is a pretty thorny question.
read full article ›We're hosting a webinar on RE Assist, a tool Real Endpoints has developed to help solve the Medicare copay challenge. RE Assist is compliant, comprehensive, timely, and flexible.
read full article ›